Ito Inhibitor Compositions for J Wave Arrhythmia Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a need for safe and effective pharmacologic treatments capable of preventing life-threatening arrhythmic events associated with J Wave Syndromes, such as Brugada syndrome and early repolarization syndrome, particularly in young infants and individuals experiencing frequent ICD shocks, as implantable cardioverter defibrillators are not ideal.

Innovation Solution

Administration of ion-channel specific and cardio-selective inhibitors, such as AR-787, which targets the transient outward potassium current (Ito) and may include additional agents like ICA augmentors and β-adrenergic agonists, to suppress electrocardiogram arrhythmic manifestations and reduce instances of ventricular fibrillation and sudden cardiac death.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If implantable cardioverter defibrillator (ICD) is used for treatment, then life-threatening arrhythmic events can be managed, but it is problematic for young infants and causes frequent inappropriate shocks

Engineering Contradiction:

Improvearrhythmia management effectivenessVSAvoidtreatment acceptability and appropriateness

Core Design Contradiction:

ReliabilityVSEase of operation

Solution Approach 1:

The patent replaces the mechanical/electrical intervention of ICD shocks with a pharmacological approach using Ito inhibitors. This substitution eliminates the need for invasive device implantation and inappropriate electrical shocks, particularly benefiting young infants who cannot tolerate ICD therapy.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

Solution Approach 2:

The patent introduces Ito inhibitors as a chemical intermediary that mediates the treatment of J wave syndromes. These inhibitors block the transient outward potassium current, thereby suppressing J wave formation and preventing arrhythmic events without requiring direct electrical intervention.

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If Ito inhibitors are administered to suppress J wave syndromes, then arrhythmic manifestations are reduced, but potential off-target effects on other ion channels may occur

Engineering Contradiction:

Improvearrhythmia prevention effectivenessVSAvoidoff-target channel effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent employs ion-channel specific and cardio-selective Ito inhibitors that are designed to act locally and selectively on the transient outward potassium current in cardiac tissue. This selectivity ensures that the therapeutic effect is concentrated on the target channel while minimizing interactions with other ion channels.

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent utilizes compounds with optimized pharmacological parameters, including selective binding affinity for Ito channels and appropriate kinetic properties. By carefully controlling these parameters, the inhibitors achieve effective suppression of J wave syndromes while maintaining a safe margin from off-target effects.

Inventive Principle:

Principle #35Parameter changes

Data Source

PatentUS20250228824A1Compositions and methods for inhibition of ITO as treatment for the j wave syndromes and hypothermia

Publication Date: 2025.07.17 SIMON FRASER UNIVERSITY

AI summary

Compositions and methods for treating J Wave Syndromes via ion-channel specific and cardio-selective inhibition of Ito are disclosed. In certain embodiments, the method includes administering a composition comprising ARumenamide-787 (AR-787) to a subject.